Oligomer Diagnostic Biomarkers
Alzheimer's Disease Diagnosis
Preclinical/ResearchActive
Key Facts
Indication
Alzheimer's Disease Diagnosis
Phase
Preclinical/Research
Status
Active
Company
About Abyssinia Biologics
Abyssinia Biologics is a preclinical-stage biotech developing highly selective monoclonal antibodies and a vaccine targeting toxic amyloid-beta oligomers for Alzheimer's disease. Founded in 2021 and operating with a virtual team, the company's platform aims to deliver greater clinical benefit with fewer side effects, such as ARIA, compared to plaque-clearing therapies. Its integrated strategy includes therapeutic, preventative, and diagnostic solutions, positioning it in the high-need, high-value neurodegenerative disease market, though it faces significant scientific, clinical, and competitive risks typical of early-stage CNS drug development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Diagnosis Drugs
| Drug | Company | Phase |
|---|---|---|
| iRS-AD | BetaSense | Research/Development |
| Afina Retinal Imaging | NeuroVision Imaging | Validation/Development |
| Aβ1-40/Aβ1-42/Tau IMR Reagents | MagQu | Commercial |
| Alzheimer's Biomarker | Aelan Cell Technologies | Test Stage |
| ABtest-Service | Araclon Biotech | Commercial |
| AlzTEST® | Neuron Biopharma | Not Specified |